A Novel, Regulated Gene Therapy (NGN-401) Study for Females With Rett Syndrome
Condition: Rett Syndrome · Sponsor: Neurogene Inc.
About this study
This study will evaluate the efficacy and safety profiles of the investigational gene therapy, NGN-401, in females with typical Rett syndrome.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (16)
| University of Alabama at Birmingham | Birmingham, Alabama, United States | — |
| UCSF Benioff Children's Hospital Oakland | Oakland, California, United States | — |
| Children's Hospital Colorado | Aurora, Colorado, United States | — |
| Nicklaus Children's Hospital Research Institute | Miami, Florida, United States | — |
| Rush University Medical Center | Chicago, Illinois, United States | — |
| Kennedy Krieger Institute | Baltimore, Maryland, United States | — |
| Boston Children's Hospital | Boston, Massachusetts, United States | — |
| Montefiore Medical Center | New York, New York, United States | — |
| UNC at Chapel Hill | Chapel Hill, North Carolina, United States | — |
| Nationwide Children's Hospital | Columbus, Ohio, United States | — |
| Children's Hospital of Philadelphia | Philadelphia, Pennsylvania, United States | — |
| Vanderbilt University Medical Center | Nashville, Tennessee, United States | — |
+ 4 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05898620